TickerTalks
Browse all tickers →
TickerTalks›$BIIB
BIBIIB

Biogen Inc.

$BIIB·$31B·Drug Manufacturers - General·Healthcare
$218.12+0.6%YTD+18.9%1Y+60.0%
Mentions · last 7 days
2026-08-18: 6 posts2026-08-19: 12 posts2026-08-20: 13 posts2026-08-21: 9 posts2026-08-22: 1 posts2026-08-23: 3 posts2026-08-24: 13 posts57+2%
Price updated 7h ago·X counts updated 6h ago
BIBIIB
$BIIBBiogen Inc.
$218.12+0.62%57 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BIIB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptCooling offAI verdict · as of 2026-08-20

Catching its breath after a run — could pick back up or fade from here.

Biogen's Q2 was a genuine beat but the FY26 EPS guide cut is doing the real work on the tape.

Biogen's Q2 print carried both the upside and downside of the turnaround simultaneously, and the guide cut is the piece the market is choosing to weight.

  • Q2 revenue of $2.73B beat the $2.45B expectation and EPS of $3.60 beat $2.96, with LEQEMBI on track toward a $1B annualized run rate and the growth-portfolio revenue exceeding legacy multiple-sclerosis revenue for the first time — that mix shift is the whole turnaround thesis.
  • Full-year FY26 EPS guidance was cut from $14.25–$15.25 to $12.00–$13.00, and that trumped the print even though the mix improvement is a bigger long-term story than the near-term earnings line.
  • Bearish framing calls out no revenue growth over the next seven or eight years per some skeptic models, plus Bernstein preferring Vertex on capital-allocation grounds — that's a real critique, though the LEQEMBI ramp complicates the flat-revenue narrative.
  • Latest quarterly revenue of $2.48B with quarterly EPS of $2.17 reflects the current cadence; gross margin near 70% and debt-to-equity around 0.35 keep the balance sheet as a strength that supports opportunistic BD.
  • At +19% YTD and +60% trailing year, the stock has already been rewarded for the LEQEMBI transition; further upside requires the growth portfolio to actually offset the legacy MS decline, not just start to.

The cooling trajectory captures the guide-cut effect on a stock that had already been anticipating the mix shift; the archetype is still turnaround because the mix inflection is real.

Agrees with X sentimentThe X read of a genuinely split debate — bulls on Q2 and LEQEMBI, bears on the guide cut and the long-term revenue outlook — captures the picture accurately, and the tape is siding with the bears until the growth portfolio proves scale.

What to watch: LEQEMBI weekly script data, Q3 growth-portfolio revenue mix, and any commentary on 2027 EPS trajectory that would either validate or refute the flat-revenue bear framing.

On the calendar: Q3 2026 earnings, expected late October

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment10 posts analyzed · as of 2026-08-05

Biogen is genuinely split — bulls celebrate Q2 revenue of $2.73B vs $2.45B est, EPS $3.60 vs $2.96 est, LEQEMBI marching toward $1B/yr, and growth-portfolio revenue exceeding legacy MS for the first time. Bears cite the lowered FY26 EPS guidance from $14.25-$15.25 to $12-$13, no revenue growth over the next 7-8 years per one skeptic, and Bernstein preferring VRTX. The guide cut is doing the work here.

Read the AI verdict + X sentiment for $BIIB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Neuroscience-focused biotech commercializing treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $BIIB.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $BIIB

Neutral — Neuroscience-focused biotech commercializing treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease; limited read-through from drug manufacturers - general macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+52.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
21.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$3.60$2.94+22.4%
Q1 2026Apr 29, 2026$3.57$3.05+17.0%
Q4 2025Feb 6, 2026$1.99$1.63+22.1%
Q3 2025Oct 30, 2025$4.81$3.88+24.0%
Next earningsThu, Oct 29·consensus EPS $2.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.5B+1.9%73.3%16.0%$2.17$696.7M
Q4 FY25$2.3B-7.1%78.2%-2.5%$-0.33$555.9M
Q3 FY25$2.5B-0.4%64.3%25.0%$3.18$1.2B
Q2 FY25$2.6B+7.3%64.2%22.2%$4.35$144.3M

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.3B$10.0B – $11.0B$12.76-$11.86 – $17.5622
FY27$10.5B$9.9B – $11.2B$16.54$12.41 – $20.2125
FY28$10.8B$10.0B – $11.8B$18.77$14.14 – $24.3924
FY29$11.1B$10.6B – $11.7B$20.71$19.37 – $22.0723
FY30$11.3B$10.8B – $11.9B$20.97$19.62 – $22.3415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 146.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 4Lloyd MinorDirector593 sh$119KSellAug 3Lloyd MinorDirector593 sh$121K
+ 14 other (9 awards · 3 exempts · 2 inkinds) in window

See when $BIIB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 123
AI summary

Biogen (BIIB) filed a Form 3 initial statement of beneficial ownership for its Chief Legal Officer. The filing discloses the new insider's initial stock ownership positions. Specific share counts and security details are in the tabular section of the form.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

Biogen held its 2026 Annual Meeting of Stockholders on June 9, 2026, with all ten director nominees elected for one-year terms through 2027. Most nominees received 100–121M 'for' votes, with Eric Rowinsky receiving the lowest support (~93.6M for) and Susan Langer the highest (~103.9M for). The meeting likely also addressed auditor ratification and compensation advisory votes, though those results are not shown in the excerpt. Standard governance event with no material impact.

SC 13D/AActivist amendmentMay 14SC 13D/A
AI summary

Biogen filed Amendment No. 1 to its Schedule 13D on Apellis Pharmaceuticals, Inc. as a final exit filing: Biogen now beneficially owns 0 shares (0.0%) of Apellis common stock, as all shares were irrevocably accepted for payment pursuant to the merger that closed May 14, 2026. This terminates Biogen's reporting obligation as a 5%+ holder of Apellis, which no longer exists as an independent public company following the acquisition. Procedural filing completing the Apellis/Biogen merger paper trail.

8-KMaterial agreementMay 148-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
AI summary

Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, consummating the Agreement and Plan of Merger dated March 31, 2026. In connection with the merger, Biogen, Apellis, and Equiniti Trust Company entered into a Contingent Value Rights (CVR) Agreement governing CVRs issued to former Apellis shareholders; Biogen's subsidiary irrevocably accepted all Apellis shares tendered. The deal is transformative for Biogen's pipeline, adding Apellis's complement-targeting franchise (notably SYFOVRE/pegcetacoplan in geographic atrophy and other complement-mediated diseases) at a cost reflected in the ~$164M Q2 IPR&D charge disclosed separately.

3New insider — initial holdingsApr 63
SC 13DActivist position (5%+)Apr 6SC 13D
8-KMaterial agreementMar 318-K — Item 1.01: Material agreement · Item 8.01: Other event
8-KOfficer or director changeMar 118-K — Item 5.02: Officer or director change
+ 23 other (5 13Gs · 5 earnings 8-Ks · 4 SC TO-Cs · 3 SC TO-T/As) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Diseaseglobenewswire.com·20h agoLEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Diseaseprnewswire.com·20h agoAllworth Financial LP Takes $1.74 Million Position in Biogen Inc. $BIIBdefenseworld.net·3d agoBiogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of “Moderate Buy” by Brokeragesdefenseworld.net·4d agoShould You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?zacks.com·5d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$NVO$JNJ$GILD$ABBV$AMGN
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport